These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9020492)

  • 21. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988.
    Huddart SN; Mann JR; Gornall P; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendsus KR
    J Pediatr Surg; 1990 Apr; 25(4):406-10. PubMed ID: 1691781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy.
    Suurmeijer AJ; Oosterhuis JW; Marrink J; De Bruin HW; Schraffordt Koops H; Sleijfer DT; Fleuren GJ
    Oncodev Biol Med; 1983; 4(4):289-308. PubMed ID: 6188132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
    J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
    Keskin S; Ekenel M; Başaran M; Bavbek S
    Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Case report of a non-seminomatous testicular neoplasm indicating marked efficacy of a combination chemotherapy of VBL, ACTD, BLM, CDDP and EX (VAB-4 combination therapy)].
    Hayashi M; Ebihara K; Urano E
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2775-7. PubMed ID: 6210063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Germ cell testicular tumors: understanding the kinetics of serum alpha-fetoprotein (AFP) during chemotherapy].
    Riedinger JM; Eche N; Chevreau C; Fargeot P
    Ann Biol Clin (Paris); 2008; 66(5):523-30. PubMed ID: 18957341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AFP and HCG in germ cell tumors.
    Bassetto MA; Franceschi T; Lenotti M; Parise G; Pancheri F; Sabbioni R; Zaninelli M; Cetto GL
    Int J Biol Markers; 1994; 9(1):29-32. PubMed ID: 7519651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
    Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
    Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of good-risk disseminated testicular cancer with cisplatin, bleomycin, and reduced-dose vinblastine.
    Pizzocardo G; Salvioni R; Zanoni F; Milani A; Piva L
    Cancer; 1986 Jun; 57(11):2114-8. PubMed ID: 2421865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Primary intracranial malignant germ cell tumor associated with abnormal high value of alpha-fetoprotein and human chorionic gonadotropin].
    Nishiyama K; Nishida K; Kusaka K; Morizumi H
    No Shinkei Geka; 1987 Dec; 15(12):1337-42. PubMed ID: 2452372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
    Massard C; Kramar A; Beyer J; Hartmann JT; Lorch A; Pico JL; Rosti G; Droz JP; Fizazi K
    Ann Oncol; 2013 Feb; 24(2):322-328. PubMed ID: 23104726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma.
    van der Gaast A; Hoekstra JW; Croles JJ; Splinter TA
    J Urol; 1991 Apr; 145(4):829-31. PubMed ID: 1706441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [False-positive elevation of alpha-fetoprotein during induction chemotherapy in patients with testicular cancer].
    Hida S; Kawakita M; Oishi K; Okada Y; Takeuchi H; Okada K; Yoshida O
    Hinyokika Kiyo; 1986 Dec; 32(12):1859-66. PubMed ID: 2435135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application.
    Price P; Hogan SJ; Horwich A
    Eur J Cancer; 1990 Apr; 26(4):450-3. PubMed ID: 1694086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.
    Stoter G; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; Jones WG; van Oosterom AT; Vendrik CP; Spaander P; de Pauw M; Sylvester R
    J Clin Oncol; 1986 Aug; 4(8):1199-206. PubMed ID: 2426419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
    J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980.
    Nørgaard-Pedersen B; Schultz HP; Arends J; Brincker H; Krag Jacobsen G; Lindeløv B; Rørth M; Svennekjaer IL
    Acta Radiol Oncol; 1984; 23(4):287-94. PubMed ID: 6208749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of disseminated seminoma.
    Einhorn LH; Williams SD
    Cancer Clin Trials; 1980; 3(4):307-13. PubMed ID: 6159120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
    Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
    J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.